WOMEN'S HEALTH: Edited by Joseph AquilinaNew evidence on prognostic features, prevention and treatment of congenital Cytomegalovirus infectionSebghati, Mercedea; Khalil, Asmaa,bAuthor Information aFetal Medicine Unit, St George's University Hospitals bVascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK Correspondence to Asma Khalil, Fetal Medicine Unit, St George's University of London, London SW17 0RE, UK. Tel: +44 203 299 8256; fax: +44 207 733 9534; e-mail: email@example.com, firstname.lastname@example.org Current Opinion in Obstetrics and Gynecology: October 2020 - Volume 32 - Issue 5 - p 342-350 doi: 10.1097/GCO.0000000000000651 Buy Metrics Abstract Purpose of review Congenital Cytomegalovirus (CMV) infection remains a major cause of lifelong disability, with no systematic screening implemented in pregnancy or the postnatal period. In this review article, we outline the preventive strategies, antenatal prognostic features and experimental therapies as well as evidence of efficacy from recent trials. Recent findings A recent randomized, double blinded, placebo-controlled study investigated the efficacy of Valaciclovir in women contracting primary CMV in the periconception period or first trimester. They concluded that Valaciclovir at a dose of 8 g/day is effective in reducing the rate of foetal CMV infection following early maternal primary infection. Administration of CMV hyperimmune globulin (HIG) was investigated in a recent randomized double-masked controlled trial. This study concluded that CMV HIG was ineffective at reducing the risk of congenital CMV among women with primary CMV in early pregnancy. Summary Congenital CMV infection remains a significant cause of disability. There is currently no vaccine available, with the best preventive strategy being patient education on transmission as well as hygiene measures to reduce risk of exposure. Experimental therapies have been investigated in recent years and there is evidence supporting the use of Valaciclovir. Data for the efficacy of CMV HIG remains inconsistent and administration is currently limited to clinical trial settings. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.